Background. Immunotherapy shows promise in treating cancer by leveraging the immune system to combat cancer cells. However, the influence of crotonylation metabolism on the prognosis and tumor environment in ccRCC patients is not fully understood. Methods. We conducted various systematic analyses, including prognosis and cluster analyses, to investigate the role of KAT2A in immunotherapy. We used qRT-PCR to compare KAT2A expression in cancer and adjacent tissues and among different cell lines. Additionally, we employed Cell Counting Kit-8, wound healing, and Transwell chamber assays to assess changes in the proliferative and metastatic ability of A498 and 786-O cells. Results. We identified three clusters related to crotonylation metabolism, each with distinct prognosis and immune characteristics in ccRCC. We categorized CT1 as immune-inflamed, CT2 as immune-excluded, and CR3 as immune-desert. A new system, CRS, emerged as an effective predictor of patient outcomes with differing immune characteristics. Moreover, qRT-PCR revealed elevated KAT2A levels in ccRCC tissues and cell lines. KAT2A was found to promote ccRCC and correlate significantly with immunosuppressive elements and checkpoints. Reducing KAT2A expression hindered ccRCC cell growth and metastasis. Conclusion. Our study highlights the critical role of crotonylation metabolism in cancer development and progression, particularly its link to poor prognosis. CRS proves to be an accurate predictor of patient outcomes and immune features in ccRCC. KAT2A shows strong associations with clinical factors and the immunosuppressive environment, suggesting potential for innovative immunotherapies in ccRCC treatment.

中文翻译：

---

巴豆酰化代谢特征的鉴定预测透明细胞肾细胞癌的总体生存期

背景。免疫疗法通过利用免疫系统对抗癌细胞来治疗癌症。然而，巴豆酰化代谢对ccRCC患者预后和肿瘤环境的影响尚不完全清楚。方法。我们进行了各种系统分析，包括预后和聚类分析，以研究 KAT2A 在免疫治疗中的作用。我们使用 qRT-PCR 比较癌症和癌旁组织以及不同细胞系之间的 KAT2A 表达。此外，我们采用 Cell Counting Kit-8、伤口愈合和 Transwell 小室检测来评估 A498 和 786-O 细胞的增殖和转移能力的变化。结果。我们确定了与巴豆酰化代谢相关的三个簇，每个簇在 ccRCC 中具有不同的预后和免疫特征。我们将 CT1 分类为免疫炎症，CT2 分类为免疫排除，CR3 分类为免疫沙漠。一种新系统 CRS 成为具有不同免疫特征的患者结果的有效预测指标。此外，qRT-PCR 显示 ccRCC 组织和细胞系中 KAT2A 水平升高。研究发现 KAT2A 可促进 ccRCC，并与免疫抑制元件和检查点显着相关。减少 KAT2A 表达会阻碍 ccRCC 细胞的生长和转移。结论。我们的研究强调了巴豆酰化代谢在癌症发生和进展中的关键作用，特别是其与不良预后的联系。事实证明，CRS 可以准确预测 ccRCC 患者的预后和免疫特征。KAT2A 显示出与临床因素和免疫抑制环境的密切相关性，表明创新免疫疗法在 ccRCC 治疗中的潜力。